Die Rolle des Endocannabinoidsystems bei der Borderline-Persönlichkeitsstörung

ZUSAMMENFASSUNG

Die Borderline-Persönlichkeitsstörung ist eine schwerwiegende psychische Erkrankung mit hoher Krankheitslast. Für ihre Behandlung besteht jedoch noch keine störungsspezifische Pharmakotherapie-Empfehlung. In der Hoffnung auf ein besseres Verständnis der Entstehung und Aufrechterhaltung der Störung sowie der Ableitung möglicher pharmakologischer Strategien besteht ein hohes Interesse an der Erforschung des Endocannabinoidsystems.

Dieses Review fasst den gegenwärtigen Stand dieses jungen Forschungsfeldes zusammen. Dabei zeigt sich eine relevante Interaktion zwischen dem Endocannabinoidsystem und anderen biologischen Stressregulationssystemen, insbesondere der Hypothalamus-Hypophysen-Nebennieren-Achse. Es gibt erst wenige Untersuchungen zu Veränderungen des Endocannabinoidsystems bei der Borderline-Persönlichkeitsstörung, deren Befunde auf eine reduzierte Aktivität des Systems hinweisen. Klinische Studien sind nötig, um die möglichen Effekte einer Augmentation des Endocannabinoidsystems bei Symptomclustern der Borderline-Störung zu erforschen.

ABSTRACT

Borderline personality disorder is a severe mental illness with a high burden of disease. However, no disease-specific psychopharmacological treatment options are currently recommended. The involvement of the endocannabinoid system in borderline personality disorder has recently become a promising target of research, with hopes to gain a better understanding of the disease and to develop new pharmacological treatment strategies.

The present review summarises this relatively young field of research. It stresses the relevant interaction between the endocannabinoid system and other biological systems involved in stress regulation, in particular the hypothalamic-pituitary-adrenal axis. First evidence speaks for a general reduction of endocannabinoid functioning in borderline personality disorder. More clinical studies are needed for a better understanding whether endocannabinoid augmentation might be a viable pharmacological strategy to reduce certain symptoms of the disorder.

Schlüsselwörter

Endocannabinoidsystem - Borderline-Persönlichkeitsstörung - Hypothalamus-Hypophysen-Nebennieren-Achse

Key words

Endocannabinoid system - borderline personality disorder - hypothalamic-pituitary-adrenal axis

Publikationsverlauf

Artikel online veröffentlicht:
06. April 2023

• Literatur

• 1 Association A. P. 5th ed. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC 2013
• 2 Jerschke S. et al Zur Behandlungsgeschichte und Versorgungssituation von Patientinnen mit Borderline-Persönlichkeitsstörung in der Bundesrepublik Deutschland. Fortschritte der Neurologie Psychiatrie 1998; 66 (12) 545-552
• 3 Torgersen S. et al A twin study of personality disorders. Comprehensive psychiatry 2000; 41 (06) 416-425
• 4 Skaug E. et al Childhood trauma and borderline personality disorder traits: A discordant twin study. Journal of psychopathology and clinical science 2022; 131: 365-374
• 5 Zanarini MC. Childhood experiences associated with the development of borderline personality disorder. Psychiatric Clinics of North America 2000; 23 (01) 89-101
• 6 Agrawal H. et al Attachment studies with borderline patients: A review. Harvard review of psychiatry 2000; 12 (02) 94-104
• 7 Krause-Utz A. et al The latest neuroimaging findings in borderline personality disorder. Current psychiatry reports 2014; 16 (03) 1-13
• 8 Bohus M. Borderline-Persönlichkeitsstörung. In: Lehrbuch der Verhaltenstherapie. Berlin: Springer; 2009
• 9 Tomko R. et al Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. Journal of personality disorders 2014; 28 (05) 734
• 10 Organization WH.. International Statistical Classification of Diseases and related health problems. 11th ed. New York: World Health Organization; 2019
• 11 Eilers R, Rosner R. Die einfache und komplexe Posttraumatische Belastungsstörung in der Praxis: Eine Übersicht und Einordnung der neuen ICD-11 Kriterien in Bezug auf Kinder und Jugendliche. Kindheit und Entwicklung 2021; 30 (03) 144-153
• 12 Ford J, Courtois C. Complex PTSD, affect dysregulation, and borderline personality disorder. Borderline Personality Disorder and Emotion Dysregulation 2014; 01 (01) 1-17
• 13 Health N, Council M. Clinical practice guideline for the management of borderline personality disorder. Melbourne: NHMRC; 2012
• 14 Lieb K, Stoffers-Winterling J. Die neuen S3-Leitlinien: Borderline Persönlichkeitsstörung. In: Psychotherapie Forum. Berlin: Springer; 2015
• 15 Ripoll L. Psychopharmacologic treatment of borderline personality disorder. Dialogues in Clinical Neuroscience 2022
• 16 Ferber S. et al Targeting the Endocannabinoid System in Borderline Personality Disorder: Corticolimbic and Hypothalamic Perspectives. Current Neuropharmacology 2021; 19 (03) 360-371
• 17 Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature Reviews Neurology 2020; 16 (01) 9-29
• 18 Hill M. et al Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology 2018; 43 (01) 80-102
• 19 Lanius R. et al A review of the neurobiological basis of trauma-related dissociation and its relation to cannabinoid-and opioid-mediated stress response: A transdiagnostic, translational approach. Current Psychiatry Reports 2018; 20 (12) 1-14
• 20 Bassir Nia A, Bender B, Harpaz-Rotem I. Endocannabinoid system alterations in posttraumatic stress disorder: a review of developmental and accumulative effects of trauma. Chronic Stress 2019; 03: 2470547019864096
• 21 Bertsch K, Herpertz S. Neurobiologische Grundlagen der Borderline-Störung: eine Integration in das ICD-11-Modell der Persönlichkeitsstörungen. Der Nervenarzt 2021; 92 (07) 653-659
• 22 Bluett R. et al Endocannabinoid signalling modulates susceptibility to traumatic stress exposure. Nature communications 2017; 08 (01) 1-18
• 23 Wingenfeld K, Wolf O. Effects of cortisol on cognition in major depressive disorder, posttraumatic stress disorder and borderline personality disorder-2014 Curt Richter Award Winner. Psychoneuroendocrinology 2015; 51: 282-295
• 24 Drews E. et al Hypothalamic-pituitary-adrenal axis functioning in borderline personality disorder: a meta-analysis. Neuroscience & biobehavioral reviews 2019; 96: 316-334
• 25 Hammoud M. et al Influence of Δ9-tetrahydrocannabinol on long-term neural correlates of threat extinction memory retention in humans. Neuropsychopharmacology 2019; 44 (10) 1769-1777
• 26 Rabinak C. et al Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans. Neurobiology of learning and memory 2014; 113: 125-134
• 27 Bilek E. et al Deficient amygdala habituation to threatening stimuli in borderline personality disorder relates to adverse childhood experiences. Biological Psychiatry 2019; 86 (12) 930-938
• 28 Wilker S. et al Endocannabinoid concentrations in hair are associated with PTSD symptom severity. Psychoneuroendocrinology 2016; 67: 198-206
• 29 Hill M. et al Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology 2013; 38 (12) 2952-2961
• 30 Schaefer C. et al Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. European archives of psychiatry and clinical neuroscience 2014; 264 (05) 459-463
• 31 Hillard C. Circulating endocannabinoids: from whence do they come and where are they going?. Neuropsychopharmacology 2018; 43 (01) 155-172
• 32 Wingenfeld K. et al Reduced levels of the endocannabinoid arachidonylethanolamide (AEA) in hair in patients with borderline personality disorder – a pilot study. Stress 2018; 21 (04) 366-369
• 33 Neumeister A. et al Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Molecular psychiatry 2013; 18 (09) 1034-1040
• 34 Kolla N. et al Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11 C] CURB positron emission tomography study. Neuropsychopharmacology 2020; 45 (11) 1834-1841
• 35 Kolla N, Boileau I, Bagby R. Higher trait neuroticism is associated with greater fatty acid amide hydrolase binding in borderline and antisocial personality disorders. Scientific Reports 2022; 12 (01) 1-10
• 36 Micale V. et al Role of the endocannabinoid system in depression: from preclinical to clinical evidence, in Cannabinoid modulation of emotion, memory, and motivation. Berlin: Springer; 2015
• 37 Herpertz S, Bertsch K. A new perspective on the pathophysiology of borderline personality disorder: a model of the role of oxytocin. American Journal of Psychiatry 2015; 172 (09) 840-851
• 38 Ho W, Kolla N. The endocannabinoid system in borderline personality disorder and antisocial personality disorder: A scoping review. Behavioral Sciences & the Law 2022
• 39 Koenig A. et al Altered hair endocannabinoid levels in mothers with childhood maltreatment and their newborns. Biological psychology 2018; 135: 93-101
• 40 Schneider P. et al Adolescent peer-rejection persistently alters pain perception and CB1 receptor expression in female rats. European Neuropsychopharmacology 2014; 24 (02) 290-301
• 41 Schneider M. et al Enhanced functional activity of the cannabinoid type-1 receptor mediates adolescent behavior. Journal of Neuroscience 2015; 35 (41) 13975-13988
• 42 Schmahl C. et al Mechanisms of disturbed emotion processing and social interaction in borderline personality disorder: state of knowledge and research agenda of the German Clinical Research Unit. Borderline personality disorder and emotion dysregulation 2014; 01 (01) 1-17
• 43 Jetly R. et al The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 2015; 51: 585-588